Drug Profile
VTX 801
Alternative Names: VTX-801Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Vivet Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hepatolenticular degeneration
Most Recent Events
- 08 Apr 2024 Pharmacodynamics and adverse event data from phase I/II GATEWAY trial in Hepatolenticular degeneration released by Vivet Therapeutics
- 28 Oct 2021 No recent reports of development identified for preclinical development in Hepatolenticular-degeneration in France (IV)
- 12 Aug 2021 VTX 801 receives Fast Track designation for Hepatolenticular degeneration [IV] (In adults) in USA